There are currently 959 clinical trials in Birmingham, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Alabama at Birmingham, University of Alabama, University of Alabama at Birmingham Cancer Center and University of Alabama-Birmingham. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
RESTORE: An RCT to Evaluate the Efficacy of the Revi System
NCT06217328
Recruiting
The Revi System is indicated for the treatment of patients with symptoms of urgency incontinence alone or in combination with urinary urgency.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
12/11/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Urinary Urge Incontinence
Register for Updates
Cancer and Aging Resilience Evaluation in Older Adults with Hematologic Malignancies: the CARE-Heme Registry
NCT05556928
Recruiting
The primary purpose of this protocol is to create a registry of older (≥50 years old) patients with Hematologic Malignancies. Our main objectives include: To understand the prevalence of frailty and geriatric impairments among patients aged ≥50y and above diagnosed with a hematologic malignancy at UAB and to gather information that would lend support for future research in this vulnerable population.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
12/11/2024
Locations: Kirklin Clinic of UAB Hospital, Birmingham, Alabama
Conditions: Multiple Myeloma, Amyloidosis, Plasma Cell Leukemia
Register for Updates
Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma
NCT05183048
Recruiting
This pilot clinical study will investigate if Zirconium-89 (89Zr) panitumumab- Positron Emission Tomography/ Magnetic Resonance Imaging (PET/MRI) imaging can more accurately determine size and location of primary tumors compared to standard of care Fludeoxyglucose (18F-FDG) -PET/MRI in newly diagnosed patients with head and neck squamous cell carcinoma (HNSCC) who are undergoing surgical resection. This study is for imaging purposes only and is not a treatment study. The results of this study wi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: UAB, Birmingham, Alabama
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)
NCT05388708
Recruiting
ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives. The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatr... Read More
Gender:
ALL
Ages:
Between 14 days and 20 years
Trial Updated:
12/11/2024
Locations: Children's of Alabama, Birmingham, Alabama
Conditions: Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
Register for Updates
Infant-Maternal Partnership and Cognitive Training Study for Preterm Infants
NCT06335524
Recruiting
This study will test the hypothesis that in preterm infants a caregiver-implemented early developmental intervention (EDI) using finger puppets to develop joint attention and encourage interactive communication with routine EDI care including Bookworm training compared with routine EDI care including Bookworm training alone will increase the Ages and Stages Questionnaire® score at 12 months corrected age.
Gender:
ALL
Ages:
Between 1 week and 17 weeks
Trial Updated:
12/11/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Child Development, Infant Development, Infant, Premature, Diseases
Register for Updates
Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia
NCT05971251
Recruiting
Study is a phase I study to determine the maximum tolerated dose of adding Loncastuximab Tesirine to Aclabrutinib in the treatment of chronic lymphocytic leukemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Chronic Lymphocytic Leukemia
Register for Updates
Exosome Cargo from Preeclampsia Patients
NCT04154332
Recruiting
Although extensively studied, the cause of preeclampsia remains uncertain other than it is thought that the placenta plays a critical role in the development of preeclampsia. Recent data revealed that exosomes released from the placenta could cause preeclampsia by transporting specific cargo responsible for the pathophysiological changes associated with the systemic disease. By isolating these exosomes from maternal blood and placental tissue in patients diagnosed with preeclampsia and studying... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
12/11/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Preeclampsia
Register for Updates
The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies
NCT06006546
Recruiting
This is a multicenter controlled interventional trial. This phase 1 trial is the first study to assess 426c.Mod.Core-C4b adjuvanted with 3M-052-AF + aluminum hydroxide suspension (Alum) in people living with HIV (PLWH).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
12/11/2024
Locations: Birmingham, Birmingham, Alabama
Conditions: Chronic HIV Infection
Register for Updates
Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH)
NCT05020535
Recruiting
This first-in-patient phase 2a pilot study will assess the safety and tolerability of MW01-6-189WH (hereafter called MW189) in patients with Intracerebral Hemorrhage (ICH).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: University of Alabama Birmingham, Birmingham, Alabama
Conditions: Intracerebral Hemorrhage
Register for Updates
Effect of Reparel Knee Sleeve with Knee Injection
NCT04859764
Recruiting
The goals of treating knee osteoarthritis (OA) is to improve or maintain quality of life, mobility and function, pain relief, and improve inflammation. The different treatment options for knee OA have been extensively studied and implemented, but the optimum treatment is still undecided. There is a belief that anti-inflammatory sleeve technology may be beneficial in treating knee OA. The purpose of this study is to determine if the Reparel™ knee sleeve results in superior mobility, functionality... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
12/09/2024
Locations: UAB Hospital Highlands, Birmingham, Alabama
Conditions: Osteoarthritis, Knee
Register for Updates
The ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy.
NCT05676476
Recruiting
The Achieve Trial is a randomized clinical trial to test whether lowering blood pressure to less than 140/90 mmHg in women with hypertensive disorders of pregnancy will prolong pregnancy.
Gender:
FEMALE
Ages:
Between 14 years and 49 years
Trial Updated:
12/08/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Preeclampsia, Gestational Hypertension, Hypertensive Disorder of Pregnancy
Register for Updates
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
NCT04981795
Recruiting
The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combination with lenalidomide.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: Alabama Oncology, Birmingham, Alabama
Conditions: Diffuse Large B-cell Lymphoma
Register for Updates